Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment

Translational Psychiatry

Volumn 7, Issue 5, 2017, Pages

  Mattei, D ^a   Ivanov, A ^b,c   Ferrai, C ^a   Jordan, P ^a   Guneykaya, D ^a   Buonfiglioli, A ^a,c   Schaafsma, W ^d   Przanowski, P ^e   Deuther Conrad, W ^f   Brust, P ^f   Hesse, S ^g   Patt, M ^g   Sabri, O ^g   Ross, T L ^h   Eggen, B J L ^d   Boddeke, E W G M ^d   Kaminska, B ^e   Beule, D ^a,b   Pombo, A ^a   Kettenmann, H ^a   Wolf, S A ^a   more..

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b BERLIN INSTITUTE OF HEALTH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^f INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MINOCYCLINE; TRANSCRIPTOME; ANTIINFECTIVE AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DENSITY; CELL SELECTION; COMPARATIVE STUDY; COMPLEMENT SYSTEM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; MATERNAL IMMUNE ACTIVATION; MENTAL PATIENT; MICROGLIA; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PHAGOCYTOSIS; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PREGNANT WOMAN; PREPULSE INHIBITION; PROGENY; SCHIZOPHRENIA; SENSORY GATING; ADULT CHILD; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNITY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; SYNAPTIC TRANSMISSION;

ADULT CHILDREN; ALZHEIMER DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNE SYSTEM PHENOMENA; MICE; MICE, INBRED C57BL; MICROGLIA; MINOCYCLINE; PHAGOCYTOSIS; PREGNANCY; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; TRANSCRIPTOME;

EID: 85026229030     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2017.80     Document Type: Article

References (86)

1. Elsayed M, Magistretti PJ. A new outlook on mental illnesses: glial involvement beyond the glue. Front Cell Neurosci 2015; 9: 468.
2. Laskaris LE, Di Biase MA, Everall I, Chana G, Christopoulos A, Skafidas E et al. Microglial activation and progressive brain changes in schizophrenia. Br J Pharmacol 2016; 173: 666-680.
3. Trepanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry 2016; 21: 1009-1026.
4. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999; 271: 126-128.
5. Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell 2014; 158: 15-24.
6. Cunningham CL, Martínez-Cerdeño V, Noctor SC. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J Neurosci 2013; 33: 4216-4233.
7. Sierra A, Encinas JM, Deudero JJP, Chancey JH, Enikolopov G, Overstreet-Wadiche LS et al. Microglia shape adult hippocampal neurogenesis through apoptosiscoupled phagocytosis. Cell Stem Cell 2010; 7: 483-495.
8. Frankle WG, Lerma J, Laruelle M. The synaptic hypothesis of Schizophrenia. Neuron 2003; 39: 205-216.
9. Toro CT, Deakin JFW. Adult neurogenesis and schizophrenia: a window on abnormal early brain development? Schizophr Res 2007; 90: 1-14.
10. Wolf SA, Melnik A, Kempermann G. Physical exercise increases adult neurogenesis and telomerase activity, and improves behavioral deficits in a mouse model of schizophrenia. Brain Behav Immun 2011; 25: 971-980.
11. Glausier JR, Lewis Da. Dendritic spine pathology in schizophrenia. Neuroscience 2013; 251: 90-107.
12. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61: 774-780.
13. Cai L, Wan C-L, He L, de Jong S, Chou K-C. Gestational influenza increases the risk of psychosis in adults. Med Chem 2015; 11: 676-682.
14. Mattei D, Schweibold R, Wolf SA. Brain in flames-animal models of psychosis: utility and limitations. Neuropsychiatr Dis Treat 2015; 11: 1313-1329.
15. Meyer U, Feldon J, Schedlowski M, Yee BK. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 2005; 29: 913-947.
16. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised doubleblind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-1193.
17. Chaves C, Marque CR, Maia-de-Oliveira JP, Wichert-Ana L, Ferrari TB, Santos AC et al. Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia. Schizophr Res 2015; 161: 439-445.
18. Ghanizadeh A, Dehbozorgi S, OmraniSigaroodi M, Rezaei Z. Minocycline as addon treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov 2014; 8: 211-215.
19. Jhamnani K, Shivakumar V, Kalmady S, Rao NP, Venkatasubramanian G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci 2013; 25: E06-E07.
20. Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol 2015; 35: 374-381.
21. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-149.
22. Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res 2014; 153: 169-176.
23. Mattei D, Djodari-Irani A, Hadar R, Pelz A, de Cossío LF, Goetz T et al. Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain Behav Immun 2014; 38: 175-184.
24. Giovanoli S, Engler H, Engler A, Richetto J, Feldon J, Riva MA et al. Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia. Transl Psychiatry 2016; 6: e772.
25. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 2012; 9: 151.
26. Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol 2014; 10: 643-660.
27. Tartaglione AM, Venerosi A, Calamandrei G. Early-life toxic insults and onset of sporadic neurodegenerative diseases-an overview of experimental studies. Curr Top Behav Neurosci 2016; 29: 231-264.
28. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 2009; 14: 992-1003.
29. Pajonk F-G, Wobrock T, Gruber O, Scherk H, Berner D, Kaizl I et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 2010; 67: 133-143.
30. Tamminga Ca, Stan AD, Wagner AD. The hippocampal formation in schizophrenia. Am J Psychiatry 2010; 167: 1178-1193.
31. Tregellas JR, Davalos DB, Rojas DC, Waldo MC, Gibson L, Wylie K et al. Increased hemodynamic response in the hippocampus, thalamus and prefrontal cortex during abnormal sensory gating in schizophrenia. Schizophr Res 2007; 92: 262-272.
32. van Erp TGM, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry 2016; 21: 585.
33. Chaves C, Zuardi AW, Hallak JEC. Minocycline as a potential treatment in the early stages of schizophrenia: a translational approach. Ther Targets Neurol Dis 2015; 2: e580.
34. Reisinger S, Khan D, Kong E, Berger A, Pollak A, Pollak DD. The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. Pharmacol Ther 2015; 149: 213-226.
35. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 2012; 13: 93-110.
36. Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T et al. Gliomaassociated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS ONE 2015; 10: e0116644.
37. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29: 15-21.
38. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30: 923-930.
39. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.
40. Holtman IR, Raj DD, Miller JA, Schaafsma W, Yin Z, Brouwer N et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun 2015; 3: 31.
41. Satoh J-I, Asahina N, Kitano S, Kino Y. A comprehensive profile of ChIP-seq-based PU.1/Spi1 target genes in microglia. Gene Regul Syst Biol 2014; 8: 127-139.
42. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-675.
43. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990; 47: 181-188.
44. Lesh TA, Niendam TA, Minzenberg MJ, Carter CS. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology 2011; 36: 316-338.
45. Horiuchi M, Wakayama K, Itoh A, Kawai K, Pleasure D, Ozato K et al. Interferon regulatory factor 8/interferon consensus sequence binding protein is a critical transcription factor for the physiological phenotype of microglia. J Neuroinflammation 2012; 9: 227.
46. Smith AM, Gibbons HM, Oldfield RL, Bergin PM, Mee EW, Faull RLM et al. The transcription factor PU.1 is critical for viability and function of human brain microglia. Glia 2013; 61: 929-942.
47. Laskaris LE, Di Biase MA, Everall I, Chana G, Christopoulos A, Skafidas E et al. Microglial activation and progressive brain changes in schizophrenia. Br J Pharmacol 2016; 173: 666-680.
48. Airas L, Dickens AM, Elo P, Marjamaki P, Johansson J, Eskola O et al. In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis. J Nucl Med 2015; 56: 305-310.
49. Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 2013; 33: 53-58.
50. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET Brain Imaging Study. Am J Psychiatry 2016; 173: 44-52.
51. Doorduin J, de Vries EFJ, Willemsen ATM, de Groot JC, Dierckx Ra, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-1807.
52. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in vivo PET study with [18F]-FEPPA. Schizophr Bull 2015; 41: 85-93.
53. Hovens I, Nyakas C, Schoemaker R. A novel method for evaluating microglial activation using ionized calcium-binding adaptor protein-1 staining: cell body to cell size ratio. Neuroimmunol Neuroinflammation 2014; 1: 82.
54. Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE 2013; 8: e60921.
55. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R et al. Microglia sculpt postnatal neural circuits in an activity and complementdependent manner. Neuron 2012; 74: 691-705.
56. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530: 177-183.
57. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci 2012; 35: 369-389.
58. Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 2014; 75: 307-315.
59. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013; 169: 337-352.
60. Oya K, Kishi T, Iwata N. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 2014; 29: 483-491.
61. Bonjoch L, Gea-Sorli S, Jordan J, Closa D. Minocycline inhibits peritoneal macrophages but activates alveolar macrophages in acute pancreatitis. J Physiol Biochem 2015; 71: 839-846.
62. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K et al. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis 2013; 4: e525.
63. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998; 95: 15769-15774.
64. Moller T, Bard F, Bhattacharya A, Biber K, Campbell B, Dale E et al. Critical databased re-evaluation of minocycline as a putative specific microglia inhibitor. Glia 2016; 64: 1788-1794.
65. Erny D, Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 2015; 18: 965-977.
66. Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci 2014; 15: 209-216.
67. Sierra A, Abiega O, Shahraz A, Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci 2013; 7: 6.
68. Minten C, Terry R, Deffrasnes C, King NJC, Campbell IL. IFN regulatory factor 8 is a key constitutive determinant of the morphological and molecular properties of microglia in the CNS. PLoS ONE 2012; 7: e49851.
69. Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009; 35: 306-328.
70. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J et al. Global quantification of mammalian gene expression control. Nature 2011; 473: 337-342.
71. Giovanoli S, Notter T, Richetto J, Labouesse MA, Vuillermot S, Riva MA et al. Late prenatal immune activation causes hippocampal deficits in the absence of persistent inflammation across aging. J Neuroinflammation 2015; 12: 221.
72. Giovanoli S, Weber-Stadlbauer U, Schedlowski M, Meyer U, Engler H. Prenatal immune activation causes hippocampal synaptic deficits in the absence of overt microglia anomalies. Brain Behav Immun 2016; 55: 25-38.
73. Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 115-121.
74. Juckel G, Manitz MP, Brune M, Friebe A, Heneka MT, Wolf RJ. Microglial activation in a neuroinflammational animal model of schizophrenia-a pilot study. Schizophr Res 2011; 131: 96-100.
75. Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science 2016; 353: aad8670.
76. Doorn KJ, Breve JJ, Drukarch B, Boddeke HW, Huitinga I, Lucassen PJ et al. Brain region-specific gene expression profiles in freshly isolated rat microglia. Front Cell Neurosci 2015; 9: 84.
77. Grabert K, Michoel T. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci 2016; 19: 504-516.
78. Olson JK. Immune response by microglia in the spinal cord. Ann N Y Acad Sci 2010; 1198: 271-278.
79. Hanamsagar R, Bilbo SD. Sex differences in neurodevelopmental and neurodegenerative disorders: focus on microglial function and neuroinflammation during development. J Steroid Biochem Mol Biol 2016; 160: 127-133.
80. Walker DG, Lue LF. Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res Ther 2015; 7: 56.
81. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 2014; 9: 20.
82. Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 2016; 8: 992-1004.
83. Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CY, Landreth G. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem 2006; 281: 20842-20850.
84. Douaud G, Groves AR, Tamnes CK, Westlye LT, Duff EP, Engvig A et al. A common brain network links development, aging, and vulnerability to disease. Proc Natl Acad Sci USA 2014; 111: 17648-17653.
85. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016; 352: 712-716.
86. Kempermann G. The neurogenic reserve hypothesis: what is adult hippocampal neurogenesis good for? Trends Neurosci 2008; 31: 163-169.